Cargando…
Nox4 as a novel therapeutic target for diabetic vascular complications
Diabetic vascular complications can affect both microvascular and macrovascular. Diabetic microvascular complications, such as diabetic nephropathy, diabetic retinopathy, diabetic neuropathy, and diabetic cardiomyopathy, are believed to be caused by oxidative stress. The Nox family of NADPH oxidases...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363438/ https://www.ncbi.nlm.nih.gov/pubmed/37321060 http://dx.doi.org/10.1016/j.redox.2023.102781 |
_version_ | 1785076625461739520 |
---|---|
author | Wang, Dongxia Li, Jiaying Luo, Gang Zhou, Juan Wang, Ning Wang, Shanshan Zhao, Rui Cao, Xin Ma, Yuxia Liu, Gang Hao, Liping |
author_facet | Wang, Dongxia Li, Jiaying Luo, Gang Zhou, Juan Wang, Ning Wang, Shanshan Zhao, Rui Cao, Xin Ma, Yuxia Liu, Gang Hao, Liping |
author_sort | Wang, Dongxia |
collection | PubMed |
description | Diabetic vascular complications can affect both microvascular and macrovascular. Diabetic microvascular complications, such as diabetic nephropathy, diabetic retinopathy, diabetic neuropathy, and diabetic cardiomyopathy, are believed to be caused by oxidative stress. The Nox family of NADPH oxidases is a significant source of reactive oxygen species and plays a crucial role in regulating redox signaling, particularly in response to high glucose and diabetes mellitus. This review aims to provide an overview of the current knowledge about the role of Nox4 and its regulatory mechanisms in diabetic microangiopathies. Especially, the latest novel advances in the upregulation of Nox4 that aggravate various cell types within diabetic kidney disease will be highlighted. Interestingly, this review also presents the mechanisms by which Nox4 regulates diabetic microangiopathy from novel perspectives such as epigenetics. Besides, we emphasize Nox4 as a therapeutic target for treating microvascular complications of diabetes and summarize drugs, inhibitors, and dietary components targeting Nox4 as important therapeutic measures in preventing and treating diabetic microangiopathy. Additionally, this review also sums up the evidence related to Nox4 and diabetic macroangiopathy. |
format | Online Article Text |
id | pubmed-10363438 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-103634382023-07-25 Nox4 as a novel therapeutic target for diabetic vascular complications Wang, Dongxia Li, Jiaying Luo, Gang Zhou, Juan Wang, Ning Wang, Shanshan Zhao, Rui Cao, Xin Ma, Yuxia Liu, Gang Hao, Liping Redox Biol Review Article Diabetic vascular complications can affect both microvascular and macrovascular. Diabetic microvascular complications, such as diabetic nephropathy, diabetic retinopathy, diabetic neuropathy, and diabetic cardiomyopathy, are believed to be caused by oxidative stress. The Nox family of NADPH oxidases is a significant source of reactive oxygen species and plays a crucial role in regulating redox signaling, particularly in response to high glucose and diabetes mellitus. This review aims to provide an overview of the current knowledge about the role of Nox4 and its regulatory mechanisms in diabetic microangiopathies. Especially, the latest novel advances in the upregulation of Nox4 that aggravate various cell types within diabetic kidney disease will be highlighted. Interestingly, this review also presents the mechanisms by which Nox4 regulates diabetic microangiopathy from novel perspectives such as epigenetics. Besides, we emphasize Nox4 as a therapeutic target for treating microvascular complications of diabetes and summarize drugs, inhibitors, and dietary components targeting Nox4 as important therapeutic measures in preventing and treating diabetic microangiopathy. Additionally, this review also sums up the evidence related to Nox4 and diabetic macroangiopathy. Elsevier 2023-06-09 /pmc/articles/PMC10363438/ /pubmed/37321060 http://dx.doi.org/10.1016/j.redox.2023.102781 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Article Wang, Dongxia Li, Jiaying Luo, Gang Zhou, Juan Wang, Ning Wang, Shanshan Zhao, Rui Cao, Xin Ma, Yuxia Liu, Gang Hao, Liping Nox4 as a novel therapeutic target for diabetic vascular complications |
title | Nox4 as a novel therapeutic target for diabetic vascular complications |
title_full | Nox4 as a novel therapeutic target for diabetic vascular complications |
title_fullStr | Nox4 as a novel therapeutic target for diabetic vascular complications |
title_full_unstemmed | Nox4 as a novel therapeutic target for diabetic vascular complications |
title_short | Nox4 as a novel therapeutic target for diabetic vascular complications |
title_sort | nox4 as a novel therapeutic target for diabetic vascular complications |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363438/ https://www.ncbi.nlm.nih.gov/pubmed/37321060 http://dx.doi.org/10.1016/j.redox.2023.102781 |
work_keys_str_mv | AT wangdongxia nox4asanoveltherapeutictargetfordiabeticvascularcomplications AT lijiaying nox4asanoveltherapeutictargetfordiabeticvascularcomplications AT luogang nox4asanoveltherapeutictargetfordiabeticvascularcomplications AT zhoujuan nox4asanoveltherapeutictargetfordiabeticvascularcomplications AT wangning nox4asanoveltherapeutictargetfordiabeticvascularcomplications AT wangshanshan nox4asanoveltherapeutictargetfordiabeticvascularcomplications AT zhaorui nox4asanoveltherapeutictargetfordiabeticvascularcomplications AT caoxin nox4asanoveltherapeutictargetfordiabeticvascularcomplications AT mayuxia nox4asanoveltherapeutictargetfordiabeticvascularcomplications AT liugang nox4asanoveltherapeutictargetfordiabeticvascularcomplications AT haoliping nox4asanoveltherapeutictargetfordiabeticvascularcomplications |